Genomic Health Screen

Comprehensive program that includes genomic screening and relevant consultation/genetic counseling.

Who is this test for?

Adults (>18 years) who wish to undergo a Genomic Health Screen to inform their health and well-being as well as to guide prospective preventative health surveillance and management.

Turnaround time is 6-12 weeks.

Tests

Basic Genomic Health Screen

- Pre-test consultation and personalized design
  - Review relevant patient medical and family history provided by individuals and/or health care professional
  - Design testing to meet any diagnostic requirements
- Sequencing
  - This test provides comprehensive risk assessment for 3 groups of monogenic (single-gene) predispositions:
    - Those for which there are consensus guidelines for surveillance and management. The monogenic predispositions reported are the medically actionable disorders defined by the American College of Medical Genetics and Genomics. This is presently 81 genes.
    - Those for which there are prescribing guidelines. The 15 pharmacogenetic variants reported are those that impact commonly prescribed medications.
    - Those for which there are risks to offspring if the parents are carriers. The 1,300 genes reported follow the principles promulgated by MacKenzie's Mission (Australian carrier screening program).
- Post-test consultation
  - Review and discuss genomic findings with medical actionability in the context of current understanding and consensus best practices for management, surveillance, and therapy.

Premium Genomic Health Screen

- This test includes the Basic Genomic Health Screen (year 1) and then extends over a 5 year period. With each year the genomic data is updated based on medical and technical advances which can include further testing, variant re-interpretation and consultation/genetic counseling.
- Reports are updated every year to include new medically actionable disorders, newly classified pathogenic and likely pathogenic variants relevant to medically actionable disorders or carrier status, additional relevant pharmacological variants, and relevant (i.e., with consensus guidelines) polygenic and epigenetic risks.

Please contact us at orders@alamyahealth.com for more information on costs and test ordering.